What is the appropriate workup and management for a female patient with abnormal hair growth (hirsutism)?

Workup and Management of Hirsutism in Females

For a female with abnormal hair growth, start by assessing the severity using the modified Ferriman-Gallwey (mFG) score, then measure early morning total testosterone if the score is ≥8, and treat with combined oral contraceptives as first-line pharmacotherapy, adding spironolactone after 6 months if response is inadequate. 1

Initial Assessment

Clinical Evaluation

Determine hirsutism severity using the mFG scoring system (9 body sites: upper lip, chin, chest, upper/lower back, upper/lower abdomen, upper arms, thighs). An mFG score ≥8 defines hirsutism in most populations, though ethnic variation exists—Asian women may have lower cutoffs (4-5), while White Iranians may require scores ≥8 2.

Look specifically for:

• Onset and progression: Sudden onset or rapid progression over months suggests androgen-secreting tumor
• Virilization signs: Clitoromegaly, increased muscularity, voice deepening, male-pattern baldness
• PCOS features: Menstrual irregularity, infertility, central obesity, acanthosis nigricans, acne
• Medication history: Anabolic steroids, valproic acid, danazol
• Other endocrinopathy signs: Cushingoid features, galactorrhea, thyroid dysfunction symptoms 1

Laboratory Workup

When to Test

Test for elevated androgens if:

• mFG score ≥8 (moderate-severe hirsutism)
• Any degree of hirsutism with sudden onset, rapid progression, or virilization
• Mild hirsutism with menstrual irregularity, infertility, or other PCOS features 1

Do NOT test isolated mild hirsutism (mFG 8-15) with regular menses and no concerning features—likelihood of finding actionable pathology is very low 1.

Initial Testing

Measure early morning (8 AM) total testosterone on days 4-10 of menstrual cycle in regularly cycling women 1. This is the single most important initial test.

Additional Testing Based on Clinical Context

If testosterone is elevated OR high clinical suspicion despite normal testosterone:

• Free testosterone (in reliable specialty laboratory) 1
• DHEAS (to assess adrenal androgen production)
• 17-hydroxyprogesterone (early morning, follicular phase) if high risk for congenital adrenal hyperplasia—Ashkenazi Jewish, Hispanic, or Slavic ethnicity 1
• Pregnancy test if amenorrheic
• Pelvic ultrasound to detect ovarian neoplasm or polycystic ovaries
• Prolactin to exclude hyperprolactinemia
• Consider Cushing's, thyroid, acromegaly testing only if other clinical features present 1

Critical pitfall: If total testosterone is normal but risk factors persist or hirsutism progresses on therapy, recheck with both total AND free testosterone in a specialty laboratory 1.

Management Strategy

First-Line Approach

For most women with patient-important hirsutism, start with combined oral contraceptives (OCPs) 1, 3. OCPs work by:

• Suppressing ovarian androgen production
• Increasing sex hormone-binding globulin (reducing free testosterone)
• Providing contraception (essential since antiandrogens are teratogenic)

Trial OCPs for at least 6 months before changing therapy—hair growth cycles require this duration to show effect 1.

Second-Line: Add Antiandrogen

If hirsutism remains patient-important after 6+ months of OCP monotherapy, add spironolactone (100-200 mg/daily) 1, 4. Spironolactone blocks androgen receptors and inhibits 5α-reductase.

Alternative antiandrogens:

• Finasteride 5 mg/daily (inhibits type 2 5α-reductase)—comparable efficacy to spironolactone but may be slightly less effective 1
• Cyproterone acetate 2 mg (in OCP formulation) or 50-100 mg/daily—not available in United States but widely used elsewhere 1

NEVER use antiandrogen monotherapy without adequate contraception due to teratogenic risk 1, 3.

Avoid flutamide—despite potential superior efficacy, hepatotoxicity risk (including liver failure and death) makes it unsuitable for routine use 1, 5.

Therapies to AVOID

• Insulin-lowering drugs (metformin, etc.)—do NOT significantly improve hirsutism despite metabolic benefits in PCOS 1, 3, 4
• Glucocorticoids—only for nonclassic congenital adrenal hyperplasia with suboptimal response to OCPs/antiandrogens 1
• GnRH agonists—reserve only for severe hyperandrogenemia (ovarian hyperthecosis) unresponsive to OCPs and antiandrogens 1

Adjunctive Hair Removal

Combine pharmacotherapy with direct hair removal methods for optimal results:

• Laser/photoepilation (alexandrite or diode lasers)—most effective for permanent hair reduction 3, 4
• Electrolysis—effective for permanent removal in localized areas 4
• Topical eflornithine—can use as adjunct; modest benefit as monotherapy 4
• Temporary methods (shaving, waxing, plucking)—safe and immediately effective but require ongoing maintenance 6

Special Considerations

For women with mild hirsutism and no endocrine disorder: Either pharmacotherapy OR direct hair removal methods are acceptable—choice depends on patient preference, cost, and access 1, 3.

For women seeking pregnancy: Discontinue antiandrogens at least 6 months before conception attempts due to teratogenic risk 5. Consider glucocorticoids for NCCAH patients seeking ovulation induction 1.

Red flags requiring urgent evaluation:

• Testosterone >200 ng/dL suggests androgen-secreting tumor
• Rapid progression over weeks-months
• Frank virilization
• Palpable abdominal/pelvic mass 1

Key message: PCOS accounts for 80-90% of hirsutism cases 7, but the evaluation algorithm ensures you don't miss rare but serious causes like androgen-secreting tumors (present in 0.2% of hyperandrogenic women, >50% malignant) 1.